Cargando…
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective
The advent of biologic agents has provided a more specific and targeted approach to the treatment of various hematological malignancies and other autoimmune disorders. Such biologic agents have been relatively well tolerated with fewer adverse events reported as compared with many other chemotherape...
Autores principales: | Kasi, Pashtoon M, Tawbi, Hussein A, Oddis, Chester V, Kulkarni, Hrishikesh S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580676/ https://www.ncbi.nlm.nih.gov/pubmed/22967460 http://dx.doi.org/10.1186/cc11304 |
Ejemplares similares
-
Rituximab and Cytokine Release Syndrome
por: Kulkarni, Hrishikesh S., et al.
Publicado: (2012) -
Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
por: Akram, Qasim, et al.
Publicado: (2016) -
Biologic predictors of clinical improvement in rituximab-treated refractory myositis
por: Reed, Ann M., et al.
Publicado: (2015) -
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018) -
Serious safety events in rituximab‐treated multiple sclerosis and related disorders
por: Vollmer, Brandi L., et al.
Publicado: (2020)